Filter Publications
Product
Year
January 2026
HMG-CoA Reductase Inhibitors (Statins) May Preserve Hepatic Function and Reduce Portal-Systemic Shunting in Compensated Advanced Chronic Liver Disease: Results from the SHUNT-V Study
| Clinical and Translational Gastroenterology
Background and Aims: Factors associated with decline of hepatic function and increase in portal-systemic shunting, which herald clinical outcome in persons with compensated cirrhosis, are poorly characterized. We used cholate challenge to evaluate the associations of liver disease etiology, concomitant diabetes, and maintenance drug therapy, with the degree of hepatic dysfunction and portal-systemic shunting.
Conclusions: Concomitant use of statins alone or in combination with metformin was independently associated with preserved hepatic function (DSI) and reduced portal-systemic shunting (SHUNT%). read more →
HepQuant SHUNT
January 2026
Hepatic cholate clearance as assessed by HepQuant-SHUNT is predictive of clinical outcomes in individuals with Fontan circulation
| International Journal of Cardiology Congenital Heart Disease
Fontan-associated liver disease [FALD] is universal in individuals with Fontan circulation [FC]. The dual cholate clearance test is a noninvasive, flow-dependent measure of liver function. We aim to explore the association between cholate clearance and clinical outcomes in this population. read more →
HepQuant SHUNT
January 2026
HepQuant DuO® Test Enhances Clinical Decision Making in Compensated Advanced Chronic Liver Disease
| Journal of Clinical Medicine | January 2026
The HepQuant DuO® test is a noninvasive, blood-based test that assesses global liver health by quantifying liver function and physiology. The test generates a disease severity index (DSI) for assessment of risk for portal hypertension and large esophageal varices (LEV) to aid in the upper endoscopy (EGD) decision, provides a definition of disease severity to aid in clinical management, and enables serial testing to monitor changes in liver health over time, either improvement or worsening.
A DSI cutpoint 18.3 was defined in a U.S. multi-center trial in advanced chronic hepatitis C (HALT-C) and validated in a second U.S. multi-center trial where the majority of cases (52%) had MASLD/MASH (SHUNT-V). In addition, the latter validation study included all common etiologies of cACLD, and a high percentage of the study subjects were overweight, obese, elderly, and had diabetes. In several studies, DSI has shown favorable diagnostic performance compared to other noninvasive tests.
Using real-world data, the analysis evaluated the impact of DSI 18.3 in the EGD
decision and in modifying decision making in patients with cACLD. read more →
HepQuant DuO
October 2025
Initial Clinical Experience With the Oral Cholate ChallengeTest: Results From the 2023–2024 Early Access Program
| Liver International Communications | October 2025
The oral cholate challenge test of liver health, intended for use in compensated advanced chronic liver disease, was launched through an Early Access Program (EAP) in 2023–2024. Tests were provided to 16 clinicians at five liver centres across the US. The tested patients (n = 129) represented a range of etiologies and stages of disease. Top clinical uses were: (1) informing the decision for endoscopy to test for varices (n = 56, 43%), (2) defining risk for large oesophageal varices (LEV) (n = 92, 71%), and (3)baseline for monitoring disease progression or treatment effects (n = 33, 26%). The test's disease severity index (DSI) stratified patients according to risk for portal hypertension and LEV: 49 (38%) low risk, 31 (24%) moderate risk and 49 (38%) high risk. The potential impact of DSI ≤ 18.3 on EGD avoidance (38%) in clinical practice replicated that which was observed in prior validation studies (41%). read more →
HepQuant DuO
November 2025
Cholate clearance: improving the assessment of liver health compared to current liver tests (LFTs)
| Gastro Hep Advances | November 2025
Current liver function tests (LFTs) either indicate late-stage disease or hepatobiliary injury but do not accurately measure liver function. True quantitative liver function tests, analogous to creatinine clearance for the kidneys, are needed for assessing liver health.
read more →
HepQuant DuO